Daily FNArena News - Australia

Australia’s prudential regulator has punished IOOF and investors, in turn, now punish the stock. The acquisition of the ANZ wealth business hangs in limbo.

Revenue growth in core plasma products is still expected as CSL embarks on new classes of therapy in its R&D pipeline.

ResMed will acquire Propeller Health, which provides connected care for patients with COPD and asthma. Brokers believe the acquisition puts ResMed at the forefront of this market.

While Ansell is targeting savings by closing three manufacturing facilities, raw material costs remain the key risk for the earnings outlook.

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments.

Metcash faces challenges while striving for a growth strategy after a focus on cost reductions, and brokers suspects FY20 will still be tough.

Coca-Cola Amatil will have another year of transition in 2019, recognising the need to invest in sales and marketing after cutting deeply into its cost base.

Aristocrat Leisure’s FY18 result failed to reach hefty expectations but brokers are undaunted, believing the opportunities that abound require an increase in investment.

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments.

The KFC Australia business of Collins Foods continues to perform well amid new menu and delivery initiatives while KFC Europe is promising but requires further work.